Biocon Ltd. partners with Laboratorios PiSA to co-develop and commercialize generic recombinant human insulin for the U.S. market, aiming to enhance access to affordable diabetes treatments.

Information on the Target

Biocon Ltd. is Asia’s leading biopharmaceuticals company, primarily recognized for its innovations in diabetes management. Its wholly owned subsidiary, Biocon SA, has recently entered into a strategic agreement with Laboratorios PiSA S.A. de C.V. (PiSA) of Mexico to co-develop and commercialize generic recombinant human insulin (rh-insulin) specifically for the U.S. market. This collaboration targets the significant demand for generic rh-insulin, which constitutes over 40% of the global $5 billion market.

This endeavor extends Biocon's successful partnership with PiSA that has spanned over a decade. PiSA holds a dominant market position in the insulin segment in Mexico, and this collaboration aims to enhance affordable access to insulin for patients. Notably, Biocon's Insulin Glargine was the first to receive approval in Mexico in 2015 under new bio-comparable pathways, reflecting both companies' commitment to providing cost-effective diabetes solutions.

Industry Overview in Mexico

The biopharmaceutical industry in Mexico has experienced substantial growth over the last few years, driven by increasing healthcare demands and an expanding pharmaceutical market. With a po